nach oben

Current Hematologic Malignancy Reports

Erschienen in:

01.09.2012 | Lymphomas (J Armitage and P McLaughlin, Section Editors)

The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways

verfasst von: Vaishalee P. Kenkre, Brad S. Kahl

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton’s tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.

Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787–800.PubMedCrossRef

Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90:1073–83.PubMedCrossRef

Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29.PubMedCrossRef

Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176:5715–9.PubMed

Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–7.PubMedCrossRef

Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851–61.PubMedCrossRef

Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108:3428–33.PubMedCrossRef

Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006;108:3135–42.PubMedCrossRef

Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303–16.PubMedCrossRef

10.

• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578-85. This is the first publication revealing the promise of BCR targeting in B cell lymphomas.

11.

Satterthwaite AB, Witte O. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–7.PubMedCrossRef

12.

Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–80.PubMedCrossRef

13.

Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–96.PubMedCrossRef

14.

Advani A, Sharman J, Smith SM. The Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase I study. Ann Oncol. 2011;22 (Suppl 4).

15.

Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.PubMedCrossRef

16.

•• O'Brien S Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow up of a phase IB/II study. Blood. 2011; 118: Abstract 983. This abstract details the phase II experience with PCI 32765 in CLL.

17.

•• Wang L, Martin P, Blum KA, et al. The Bruton’s Tyrosine Kinase Inhibitor PCI-32765 is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Blood. 2011;118: Abstract 442. This abstract details the phase II experience with PCI 32765 in MCL.

18.

Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–4.PubMedCrossRef

19.

• Furman RR, Byrd JC, Brown JR et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood. 2010; 116: Abstract 55. This abstract details the phase I experience with CAL 101 in CLL.

20.

• Kahl BS, Byrd JC, Flinn IW, et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood. 2010; 116: Abstract 1777. This abstract details the phase I experience with CAL 101 in NHL.

21.

De Vos S, MT S, IW F. A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 2011;118:Abstract 2699.

22.

Sharman J, de Vos S, Leonard JP. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood 2011;118:Abstract 1787.

Titel: The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways
verfasst von: Vaishalee P. Kenkre
Brad S. Kahl
Publikationsdatum: 01.09.2012
Verlag: Current Science Inc.
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 3/2012
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-012-0127-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell Lymphomas

Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma

Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?

Lymphomatoid Granulomatosis and Other Epstein-Barr Virus Associated Lymphoproliferative Processes

Early Interim PET Scans in Diffuse Large B-Cell Lymphoma: Can There Be Consensus About Standardized Reporting, and Can PET Scans Guide Therapy Choices?

Hodgkin Lymphoma in Patients with HIV Infection: A Review

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie